Clinical Trial: Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
Brief Summary: The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
Detailed Summary:
Sponsor: Changchun Keygen Biological Products Co., Ltd.
Current Primary Outcome: Seroconversion rate and GMTs for live attenuated varicella vaccine [ Time Frame: 35-42 days after the first and second doses ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Occurrence of adverse events [ Time Frame: within 30 days after each vaccination ]
Original Secondary Outcome: Same as current
Information By: Changchun Keygen Biological Products Co., Ltd.
Dates:
Date Received: March 4, 2013
Date Started: March 2013
Date Completion:
Last Updated: October 14, 2013
Last Verified: October 2013